Abstract:Enterotoxigenic Escherichia coli (ETEC) is one of the most common bacterial causes of diarrhea-associated morbidity and mortality, particularly among infants and young children in developing countries. Still, the true impact on child and traveler health is likely underestimated. There are currently no licensed vaccines for ETEC, but studies indicate high public health impact, cost-effectiveness, and feasibility of immune protection through vaccination. ETEC vaccine development remains a World Health Organization priority. Traditionally, ETEC vaccine development efforts have focused on inducing antitoxin and anticolonization antigen immunity, as studies indicate that antibodies against both antigen types can contribute to protection and thus have potential for vaccines. Leading cellular vaccine candidates are ETVAX (a mixture of four inactivated strains) and ACE527 (a mixture of three live attenuated strains), both of which have been found to be safe and immunogenic in Phase 1/2 trials. ETVAX is the furthest along in development with descending-age studies already underway in Bangladesh. Other ETEC vaccine candidates based on protein subunits, toxoids (both LT and ST), or novel, more broadly conserved ETEC antigens are also under development. Of these, a protein adhesin-based subunit approach is the most advanced. Impact and economic models suggest favorable vaccine cost-effectiveness, which may help expand market interest in ETEC vaccines. Combination vaccine formulations may help improve the economic case for development and use, and better point-of-care diagnostics will help to raise awareness of the true health burden of ETEC and highlight the potential public health benefit of ETEC vaccine introduction. Better diagnostics and vaccine demand forecasting will also improve vaccine development financing and support accelerated uptake once a licensed vaccine becomes available.

Trapping cations in specific positions in tuneable "artificial cell" channels: new nanochemistry perspectives.

Status of vaccine research and development for enterotoxigenic Escherichia coli

Progress and Hurdles in the Development of Vaccines Against Enterotoxigenicescherichia Coliin Humans

Confronting Challenges to Enterotoxigenic Escherichia coli Vaccine Development

Current Perspectivesin Pathogenesis and Antimicrobial Resistance of Enteroaggregative Escherichia Coli.

Special Issue on Enterotoxigenic Escherichia coli (ETEC) Vaccines: ETEC Infection and Vaccine-Mediated Immunity

A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high-grade non-Hodgkin's lymphoma and cardiac risk factors.

Current Progress in Developing Subunit Vaccines Against Enterotoxigenic Escherichia Coli-Associated Diarrhea

Review of Newly Identified Functions Associated with the Heat-Labile Toxin of Enterotoxigenic Escherichia Coli

The Diversity of Escherichia coli Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen

Animal Enterotoxigenic Escherichia coli

Conservation and global distribution of non-canonical antigens in Enterotoxigenic Escherichia coli

Socioeconomic Disparities and Metabolic Risk in Veterans with Serious Mental Illness

Transcriptional modulation of enterotoxigenic Escherichia coli virulence genes in response to epithelial cell interactions

Contrast echocardiography of the inferior vena cava.

Progress and Challenges in Vaccine Development Against Enterotoxigenic Escherichia Coli (Etec)-Associated Porcine Post- Weaning Diarrhoea (PWD)

Update on vaccines for enteric pathogens

Vaccine development for enteric bacterial pathogens: Where do we stand?

Enteric infections and the vaccines to counter them: Future directions

On the third peptide active on smooth muscle in the skin of Rana nigromaculata hallowell.

Host-derived CEACAM-laden vesicles engage enterotoxigenic E. coli for elimination and toxin neutralization.